German biotechnology firm MorphoSys has completed the safety run-in phase of its Phase II L-MIND trial of MOR208 combined with lenalidomide, to treat relapsed or refractory diffuse large B cell lymphoma (DLBCL).

MOR208 is an immunotherapeutic Fc-enhanced antibody that targets CD19, which is largely expressed in different B-cell malignancies such as DLBCL and chronic lymphocytic leukemia (CLL).

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The Fc-enhancement of MOR208 triggers antibody-dependent, cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).

The MOR208 fuses with CD19, thereby inducing a direct apoptosis.

"We continue to investigate MOR208 in combination with lenalidomide as a potential treatment for patients with DLBCL."

The Phase II L-MIND trial is a single-arm, open-label, multicentre study of MOR208, involving about 80 patients with relapsed or refractory DLBCL who have two prior treatment histories, including an anti-CD20 targeting therapy (rituximab).

Patients applicable to high-dose chemotherapy and autologous stem cell transplantation are qualified for the study.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

It is primarily focused to determine the overall response rate (ORR).

The secondary endpoints of the trial are to determine duration of response (DoR), progression-free survival (PFS) and overall survival (OS), as well as testing the drug combination's safety and pharmacokinetic profile of MOR208.

Six patients who had been administered with MOR208 in combination with lenalidomide have displayed no negative safety signals.

MorphoSys chief development officer Dr Arndt Schottelius said: "We continue to investigate MOR208 in combination with lenalidomide as a potential treatment for patients with DLBCL.

“This is part of our broader initiative to develop MOR208 as an antibody backbone for a variety of combination partners.

“We are pleased with the initial safety run-in results from the L-MIND trial, which showed no unexpected safety signals."

The company is planning to continue with the study.

Clinical Trials Arena Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Clinical Trials Arena Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving clinical trials industry advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now